Platelet inhibitors and bleeding in cardiac surgical patients.
Where this comes from
- Record sourced from PubMed, PMID 10966005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A variety of measures may affect bleeding and transfusion requirements in abciximab-treated patients. These measures include recognition of the risk factors for increased bleeding and transfusion requirements, use of proper transfusion practices, conservation or increasing of red cell mass, appropriate heparin dosing and protamine reversal, reversal of anticoagulation, awareness of factors that affect activated clotting time (ACT), and appropriate anticoagulation for cardiopulmonary bypass.
Medical subject headings
- Cardiac Surgical Procedures
- Platelet Aggregation Inhibitors
- Postoperative Hemorrhage